Atara Biotherapeutics Inc. (AT20)
XSTU 
Summary
AT20 Chart
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atara Biotherapeutics Inc. (AT20) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Atara Biotherapeutics Inc. ever had a stock split?
Atara Biotherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anhco Nguyen CEO | XSTU Exchange | US0465132068 ISIN |
| US Country | 14 Employees | - Last Dividend | 20 Jun 2024 Last Split | 16 Oct 2014 IPO Date |
Overview
Atara Biotherapeutics, Inc. is a pioneering biotechnology firm focused on developing groundbreaking therapies for patients dealing with solid tumors, hematologic cancers, and autoimmune diseases, operating across the United States and the United Kingdom. Founded in 2012 with its headquarters nestled in Thousand Oaks, California, Atara Biotherapeutics has swiftly emerged as a leader in the biotech industry, dedicated to the discovery and development of innovative treatment options. This commitment is further evidenced by its strategic research collaboration agreements with notable institutions such as the Memorial Sloan Kettering Cancer Center and the Council of the Queensland Institute of Medical Research, enabling the company to leverage cutting-edge scientific research for therapy development.
Products and Services
- Tab-cel (tabelecleucel): This is Atara Biotherapeutics' flagship T-cell immunotherapy program, currently in Phase 3 clinical trials. It is designed to treat Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease, along with nasopharyngeal carcinoma. Through the manipulation and enhancement of T-cells, tab-cel aims to provide a targeted approach to cancer therapy, highlighting the company's focus on innovative cancer treatment solutions.
- ATA3219: A part of Atara’s promising CAR T immunotherapy pipeline, ATA3219 is currently undergoing Phase 1 clinical trials. It represents the company’s efforts to expand its portfolio in treating B-cell malignancies, demonstrating a commitment to leveraging CAR T technology for the treatment of various cancers.
- ATA3431: Still in the preclinical trial phase, ATA3431 is another integral part of Atara's CAR T immunotherapy endeavors. It’s aimed at treating B-cell malignancies and autoimmune diseases. Though still in the early stages of development, ATA3431 underscores Atara Biotherapeutics' dedication to exploring and advancing therapies for a range of complex diseases.
- ATA188: This product is in Phase 2 clinical trials and is focused on treating multiple sclerosis, an autoimmune disease. ATA188 embodies Atara's commitment to diversifying its therapeutic offerings beyond oncology, showcasing its innovative approach towards tackling autoimmune diseases through advanced biotechnological methods.
